Skip to main content

Table 1 Patient characteristics (n = 12)

From: Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

Median age, yrs. (range)

66 (48 – 78)

 Gender

 

  Male/Female

9/3

 PS

 

  0/1

3/9

 Histology

 

  Adeno/Large/Other

7/1/4

 Clinical Stage

 

  IIIB/IV

3/9

 Smoking History

 

  Current/Ex/Never

1/8/3

 EGFR mutation

 

  Positive/Negative

2/10

 Best response to prior chemo

 

  PR/SD/PD/NE

3/5/3/1

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us